HomeCompareRTNXF vs XYLD

RTNXF vs XYLD: Dividend Comparison 2026

RTNXF yields 2500.00% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RTNXF wins by $80609755877.34M in total portfolio value
10 years
RTNXF
RTNXF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RTNXF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — RTNXF vs XYLD

📍 RTNXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRTNXFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RTNXF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RTNXF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RTNXF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, RTNXF beats the other by $63,520,143,069,577,200.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RTNXF + XYLD for your $10,000?

RTNXF: 50%XYLD: 50%
100% XYLD50/50100% RTNXF
Portfolio after 10yr
$40304877938.70M
Annual income
$37,364,790,040,930,984.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RTNXF right now

RTNXF
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-22.6
Piotroski
4/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RTNXF buys
0
XYLD buys
0
No recent congressional trades found for RTNXF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRTNXFXYLD
Forward yield2500.00%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$80609755877.37M$25.3K
Annual income after 10y$74,729,580,081,858,750.00$3,219.02
Total dividends collected$80198875900.38M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: RTNXF vs XYLD ($10,000, DRIP)

YearRTNXF PortfolioRTNXF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$260,700$250,000.00$10,818$1,098.39+$249.9KRTNXF
2$6,370,070$6,091,121.50$11,738$1,222.51+$6.36MRTNXF
3$145,912,632$139,096,656.81$12,774$1,364.64+$145.90MRTNXF
4$3,133,830,814$2,977,704,297.75$13,944$1,527.86+$3133.82MRTNXF
5$63,122,812,060$59,769,613,088.96$15,270$1,715.87+$63122.80MRTNXF
6$1,192,683,724,131$1,125,142,315,226.76$16,775$1,933.09+$1192683.71MRTNXF
7$21,144,559,711,004$19,868,388,126,183.19$18,490$2,184.87+$21144559.69MRTNXF
8$351,818,906,448,043$329,194,227,557,269.44$20,450$2,477.63+$351818906.43MRTNXF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$22,697$2,819.19+$5495491397.65MRTNXF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$25,280$3,219.02+$80609755877.34MRTNXF

RTNXF vs XYLD: Complete Analysis 2026

RTNXFStock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Full RTNXF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this RTNXF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RTNXF vs SCHDRTNXF vs JEPIRTNXF vs ORTNXF vs KORTNXF vs MAINRTNXF vs QYLDRTNXF vs JEPQRTNXF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.